Review of a promising new agent - Pemetrexed disodium

被引：60

作者：

Paz-Ares, L

Bezares, S

Tabernero, JM

Castellanos, D

Cortes-Funes, H

机构：

[1] Univ Madrid, Hosp 12 Octubre, Med Oncol Serv, Dept Med Oncol, E-28041 Madrid, Spain

[2] Univ Barcelona, Hosp Gen Valle Hebron, Dept Med Oncol, Barcelona, Spain

来源：

CANCER | 2003年 / 97卷 / 08期

关键词：

antifolate antimetabolite; pyrimidine synthesis; purine synthesis; thymidylate synthase;

D O I：

10.1002/cncr.11279

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pemetrexed disodium (ALIMTa(TM), [pemetrexed], LY231514; Eli Lilly and Company; Indianapolis, IN), a novel antifolate antimetabolite with multiple enzyme targets involved in both pyrimidine and purine synthesis, has entered clinical trials due to its favorable pleclinical profile. Many studies utilizing the drug, as a single or combination agent, are currently ongoing, including Phase III trials in mesothelioma, nonsmall cell lung carcinoma (NSCLC) and pancreatic cancer. Promising feasibility and activity data have been obtained with pemetrexed in combination with platinum compounds and gemcitabine. The supplementation with daily oral folate could reduce the incidence of hematologic toxicities while preserving the antitumor activity of pemetrexed. (C) 2003 American Cancer Society.

引用

页码：2056 / 2063

页数：8